Pilot to streamline international inspections

The European Directorate for the Quality of Medicines has established bilateral confidentiality agreements with the U.S. FDA and the Australian Therapeutic Goods Administration to share information regarding inspections of active pharmaceutical ingredients (API) and excipients manufacturers. The three organizations are involved in a pilot project to rationalize international good manufacturing practices (GMP) inspections. Release

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)